Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease, specifically to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.
EuroPCR 2024: Primary Outcomes from PINNACLE I Clinical Trial Establish Safety and Effectiveness of Elixir Medical’s Hertz Contact Intravascular Lithotripsy System for Calcium Fragmentation in Moderate to Severe Calcified Coronary Artery Lesions
Hertz Contact intravascular lithotripsy, as validated by PINNACLE I data, offers an effective and safe treatment option for patients with short procedure time, simple learning curve, and utility in treatment of a broad range of moderate to severe calcified lesions.
EuroPCR 2024: Elixir Medical’s Late-Breaking 12-Month Data Demonstrate Significant Improvement in Safety and Effectiveness of World’s First Site-Specific Antithrombotic Therapeutic Compared to DES
Clinical research comparing DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific antithrombotic therapeutic (TRx) coating versus a contemporary drug-eluting stent (DES), results demonstrated a statistically significant lower TLF rate with DESyne BDS Plus than DES.
EuroPCR 2024: Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years
Clinical results show statistically significant benefit with DynamX bioadaptor over Resolute Onyx at two years, including a 65% reduction in TLF rate (1.9% versus 5.5%; p=0.046), driven by low adverse events across all components of the composite endpoint with DynamX compared to DES.
Elixir Medical To Announce Data from Three Platforms Designed to Transform Cardiovascular Disease Treatment at EuroPCR 2024, Including Two Late-Breakers
Researchers will present results from the BIOADAPTOR RCT, studying DynamX® bioadaptor vs. DES; PINNACLE I, which reviews the novel LithiX Hertz Contact Intravascular Lithotripsy technology; and one-year results from DESyne BDS Plus RCT, a study of the novel TRx site-specific antithrombotic therapeutic.
King Fahad Armed Forces Hospital Begins Trial of New Bioadaptive Angioplasty Procedure for Heart Disease Treatment
King Fahad Armed Forces Hospital is the first in the Kingdom of Saudi Arabia to begin clinical research and offer a new type of angioplasty procedure with the DynamX® Bioadaptor, a novel coronary implant designed to restore vessel function in patients with coronary artery disease (CAD).
Elixir Medical Completes Submission of DynamX Coronary Bioadaptor System to Japan’s PMDA Agency for Regulatory Approval
“Our submission for approval in Japan is an exciting milestone for the company and industry,” said Motasim Sirhan, CEO of Elixir Medical.
Job Post Template
Major Duties and Responsibilities Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla […]
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
EuroPCR 2023: Late-Breaking Clinical Data Demonstrate Elixir Medical’s Dynamx Bioadaptor Restores Vessel Motion and Function with Better Effectiveness at 12 Months Compared to a Leading Drug-Eluting Stent (DES)
Clinical data demonstrates Dynamx Bioadaptor restores vessel motion and function with better effectiveness than competitors.